Source: https://www.ghsg.org/literatur-2005
Timestamp: 2019-04-23 20:44:22+00:00

Document:
Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A; German Hodgkin's Lymphoma Study Group. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005; 23(30):7555-64.
Darabi K, Sieber M, Chaitowitz M, Braitman LE, Tester W, Diehl V.Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients. Leuk Lymphoma 2005; 46(12):1715-20.
Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Dühmke E, Müller-Hermelink K, Diehl V; German Hodgkin's Study Group. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005; 23(22):5052-60.
Glossmann JP, Staak JO, Nogova L, Diehl V, Scheid C, Kisro J, Reis HE, Peter N, Engert A, Josting A. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Ann Hematol. 2005; 84(8):517-25.
Josting A, Nogova L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Mueller R-P, Diehl V, Engert A. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's Lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005; 23 (7): 1522-1529.
Josting A, Rudolph C, Mapara M, Glossmann JP, Sieniawski M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Kisro J, Metzner B, Berdel WE, Diehl V, Engert A. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005; 16(1):116-23.
Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A. Role of hematotoxicity in female patients with Hodgkin’s lymphoma. J Clin Oncol 2005; 23(31): 8003-11.
Nogova L, Reineke T, Eich HT, Josting A, Müller-Hermelink HK, Wingbermühle K, Brillant C, Gossmann A, Oertel J, Bollen MV, Müller R-P, Diehl V, Engert A. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005; 16 (10): 1683-1687.
Rüffer JU, Ballova V, Glossmann J, Sieber M, Franklin J, Nogova L, Diehl V, Josting A; German Hodgkin Study Group. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Leuk Lymphoma. 2005 Nov;46(11):1561-7.
Shimabukuro-Vornhagen A, Haverkamp H, Engert A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V, Josting A. Lymphocyte-rich classical Hodgkin lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin’s Study Group trials. J Clin Oncol 2005; 23 (24):5739-5745.
Smardova L, Engert A, Haverkamp H, Raemakers J, Baars J, Pfistner B, Diehl V, Josting A. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma. 2005; 46(7):1017-22.
Weihrauch MR, Manzke O, Beyer M, Haverkamp H, Diehl V, Bohlen H, Wolf J, Schultze JL. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res. 2005 Jul 1;65(13):5516-9.
Behringer K, Diehl V. Twenty-five years clinical trials of the German Hodgkin Study Group (GHSG). Eur J Haematol Suppl. 2005; 75(66):21-5.
Behringer K, Diehl V. Behandlung fortgeschrittener Stadien des Hodgkin-Lymphoms. Der Onkologe, 2005; 11:942-947.
Behringer K, Engert A. Spätschäden nach Behandlung des Hodgkin-Lymphoms. Der Onkologe, 2005; 11:959-967.
Borchmann P, Schnell R, Engert A. Immunotherapy of Hodgkin's lymphoma. Eur J Haematol Suppl. 2005; 75(66):159-65.
Diehl V, Klimm B. Re D. Hodgkin lymphoma: a curable disease: what comes next? Eur J Haematol 2005; 75 (66):6-13.
Draube A, Behringer K, Diehl V. German Hodgkin's Lymphoma Study Group trials: lessons from the past and current strategies. Clin Lymphoma Myeloma. 2006; 6(6):458-68.
Eich HT, Müller R-P. The radiotherapy reference panel - experiences and results of the German Hodgkin Study Group (GHSG). Eur J Haematol 2005; 75(66):98-105.
Eich HT, Hansemann K, Müller RP. Behandlung früher Stadien des Hodgkin-Lymphoms unter dem Aspekt der Qualitätssicherung. Der Onkologe, 2005; 11:924-932.
Engert A, Müller RP, Diehl V. Hodgkin-Lymphom. Unverändert Handlungsbedarf. Der Onkologe, 2005; 11:907.
Gossmann A, Eich HT, Engert A, Josting A, Müller R-P, Diehl V, Lackner K-J. CT and MR imaging in Hodgkin’s disease – present and future. Eur J Haematol 2005; 75(66):83-89.
Goßmann A, Dietlein M, Kobe C, Naumann R. Diagnostik des Hodgkin-Lymphoms — state of the art. Der Onkologe, 2005; 11:910-916.
Josting A, Schmitz N. Behandlung von Progressen und Rezidiven des Hodgkin-Lymphoms. Der Onkologe, 2005; 11:948-958.
Josting A, Autologous transplantation in relapsed and refractory Hodgkin's disease. Eur J Haematol Suppl. 2005; 75(66):141-5.
Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica. 2005; 90(12):1680-92.
Klimm B, Diehl V, Pfistner B, Engert A. Current treatment strategies of the German Hodgkin Study Group (GHSG). Eur J Haematol Suppl. 2005; 75(66):125-34.
Klimm B, Engert A. Behandlung mittlerer Stadien beim Hodgkin-Lymphome. Der Onkologe, 2005; 11:933-941.
Klimm B, Engert A, Diehl V. First-line treatment of Hodgkin's lymphoma. Curr Hematol Rep. 2005; 4(1):15-22.
Klimm B, Diehl V, Engert A. [Hodgkin's disease]. Rev Med Suisse. 2005; 1(44):2872-7.
Klimm B, Josting A, Diehl V, Engert A. Relapsed and refractory Hodgkin’s Lymphoma. Hematology – the european hematology association program 2005; 1(1):172-175.
Mattle V, Behringer K, Engert A, Wildt L. Female fertility after cytotoxic therapy--protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur J Haematol Suppl. 2005; 75(66):77-82.
Müller R-P, Eich HT. The developement of quality assurance of radiotherapy within the German Hodgkin Study Group (GHSG) - Introduction, continuing work and results of the radiotherapy reference panel. Strahlenther Onkol 2005; 181(9):557-566.
Nogova L, Reineke T, Josting A, Müller-Hermelink HK, Eich HT, Behringer K, Müller R-P, Diehl V, Engert A. Lymphocyte-predominant and classical Hodgkin’s Lymphoma – comparison of outcomes. Eur J Haematol 2005; 75 (66):106-110.
Re D, Thomas R, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005; 105:4553-60.
Re D, Thomas RK, Zander T, Diehl V. Problems and promises of targeted therapy for Hodgkin's lymphoma. Nat Clin Pract Oncol. 2005; 2(1):2-3.
Re D, Küppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol. 2005; 23(26):6379-86.
Re D, Borchmann P. Experimentelle Therapie des Hodgkin-Lymphoms. Der Onkologe, 2005; 11:968-976.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.